Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: A randomized double-blind trial

Chinese Medical Journal

Volumn 126, Issue 10, 2013, Pages 1867-1871

  Li, Ting ^a   Chen, Shun Le ^a   Dai, Qing ^a   Han, Xing Hai ^b   Li, Zhan Guo ^c   Wu, Dong Hai ^d   Zhang, Xiao ^e   Gu, Jie Ruo ^f   Yang, Nan Ping ^g   Sun, Ling Yun ^h   Zhang, Miu Jia ⁱ   Li, Xing Fu ^j   Bao, Chun De ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g SICHUAN UNIVERSITY   (China)

^h THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

ⁱ THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^j SHANDONG UNIVERSITY   (China)

more..

Author keywords

Arthritis; Cyclooxygenase 2; Etoricoxib; Gout; Indometacin

Indexed keywords

CYCLOOXYGENASE 2; ETORICOXIB; INDOMETACIN;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CHILL; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROENTERITIS; GOUT; HAND PARESTHESIA; HEMATURIA; HUMAN; INTESTINE DISTENSION; LEG EDEMA; LIKERT SCALE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF EVALUATION; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; SWELLING; UREA BLOOD LEVEL; URINALYSIS; VERTIGO;

ADULT; AGED; ARTHRITIS, GOUTY; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; PYRIDINES; SULFONES;

EID: 84877867995     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122892     Document Type: Article

References (22)

1. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550.
2. Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, et al. Rheumatic diseases in China. Arthritis Res Ther 2008; 10: R17.
3. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682-686.
4. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999; 59: 1799-1806, 1810.
5. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422-1426.
6. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803-805.
7. Lomen PL, Turner LF, Lamborn KR, Winblad MA, Sack RL, Brinn EL. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986; 80: 134-139.
8. Ruotsi A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol Suppl 1978; (21): 15-17.
9. Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8-16.
10. Thompson M, Percy JS. Further experience with indomethacin in the treatment of rheumatic disorders. Br Med J 1966; 1: 80-83.
11. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000; 43: 978-987.
12. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 11-18.
13. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-2111.
14. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo-and active-comparator-controlled clinical trial. Clin Ther 1999; 21: 1653-1663.
15. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001; 23: 228-241.
16. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998; 91: 1769-1776.
17. Iniguez MA, Pablos JL, Carreira PE, Cabre F, Gomez-Reino JJ. Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br J Rheumatol 1998; 37: 773-778.
18. Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-1492.
19. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50: 598-606.
20. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
21. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890.
22. Agrawal NG, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001; 41: 1106-1110.